Enhancing Cardiac Rehabilitation Through Behavioral Nudges

Coronary Artery Disease Clinical Trial

Official title:

Enhancing Cardiac Rehabilitation Adherence Through Home-based Rehabilitation and Behavioral Nudges: ERA Nudge

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03834155
• Other study ID #: 18-1290
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2019
• Est. completion date: September 30, 2023

Study information

• Verified date: August 2021
• Source: Denver Health and Hospital Authority
• Contact: Kevin H Andresen, MPH
• Phone: 303-602-4859
• Email: kevin.andresen[@]dhha.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adherence to cardiac rehabilitation is poor, and worse for minorities, women, and those with lower levels of education. Patients less likely to be referred to and complete cardiac rehab are at highest risk of adverse outcomes and thus have the most to gain from participation in cardiac rehab. To improve participation, healthcare systems need to limit barriers to enrollment and promote adherence to rehabilitation.

Description:

This study aims to (1) iteratively develop and program a theoretically informed technology-based nudge message library for a diverse patient population using multiple and iterative N of 1 within subject studies. Investigators will also engage patient, provider and health systems stakeholders in designing and refining the messages. (2)Develop a one-page decision aid tool to present information designed with principles of shared decision making including pros and cons of hospital and home-based rehabilitation. Investigators will engage patients, providers, and health systems stakeholders to provide feedback on the information sheet. (3) Conduct a 2x2 factorial design randomized trial of a) choice and b) nudge messaging to improve primary outcome of CR adherence. Secondary outcomes will include enrollment and completion of CR, exercise capacity, patient engagement, quality of life, hospitalizations, and healthcare utilization. The study will additionally evaluate the interventions using a mixed methods approach applying the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework and a cost-effectiveness analysis. The cost-effectiveness analysis sub-study will evaluate the implementation cost of home-based and hospital-based cardiac rehabilitation programs in addition to the incremental cost effectiveness ratios for each intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 280
• Est. completion date: September 30, 2023
• Est. primary completion date: March 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Diagnosis of acute myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, valvular heart surgery, chronic stable angina, and/or chronic stable heart failure with left ventricular systolic dysfunction.
• 18 year of age or older
• Access to a cell phone with text messaging capability
• English or Spanish speaking

Exclusion Criteria:

• Medical director's decision based on high-risk assessment
• Enrolled in hospice or palliative care
• Being intoxicated or otherwise unable to consent to participate

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Angina, Stable
• Chronic Stable Angina
• Chronic Stable Heart Failure
• Coronary Artery Disease
• Infarction
• Myocardial Infarction
• Percutaneous Coronary Intervention
• Valvular Disease

Intervention

Other:
• Hospital-based CR + Movn Application
Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
• Choice of Hospital or home-based CR + Movn Application
Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
• Hospital-based CR + Movn Application + Nudge
Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
• Choice of Hospital or home-based CR + Movn Application + Nudge
Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.

Locations

Country	Name	City	State
United States	Denver Health and Hospital Authority	Denver	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
Denver Health and Hospital Authority

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adherence to cardiovascular rehabilitation measured by self-report in the Movn Application or through EHR/exercise physiologist report in RedCap	Attendance for 4 weeks (8 or more) exercise sessions for hospital-based CR or logging exercise data for 4 weeks for home-based rehabilitation.	12 weeks
Secondary	Active enrollment of 280 DH participants	Attending one visit following baseline visit or logging exercise data at least once for home-based CR.	3.5 yrs
Secondary	Completion of cardiovascular rehabilitation as defined by attending or logging 18 exercise sessions	Attending or logging 18 exercise sessions	12 weeks
Secondary	Exercise capacity measured by a 6-minute walk test.	Exercise capacity will be measured at the index visit, 6 weeks, 12 weeks.	12 weeks
Secondary	Patient activation and engagement will be measured using the 13-item Patient Activation Measure (PAM)	The low-literacy version of the 13-item Patient Activation Measure (PAM), both in English and Spanish, will be used to assess the effect of the intervention on patient activation. This validated and predictive tool assesses patient knowledge, skill and confidence in self-management. A single point change in PAM score is clinically meaningful and increases in the PAM are associated with increased self-management behavior. The PAM will be measured at the index visit, 6 weeks, 12 weeks.	12 weeks
Secondary	Reported quality of life measured by Ferrans and Powers Quality of Life Index	The Ferrans and Powers Quality of Life Index (QLI) will be used to assess quality of life. The QLI is a 35 question instrument that uses a 6 point scale ranging from "very unimportant (lower end of the scale)" to "very important (higher end of the scale)". The outcomes of these scales are averaged to compute the total score. The QLI is valid, reliable, sensitive to change in both CR and PR populations, and is available in English and in Spanish. The QLI will be administered at the index visit, 6 weeks and 12 weeks.	12 weeks
Secondary	Number of participants hospitalized over four months using EHR review and ICD-10s	All-cause hospitalizations will be ascertained via the EHR using ICD-10 codes. Follow-up for hospitalizations will occur through 6 months.	6 months
Secondary	Number of participants who attend or log of 36 cardiovascular rehabilitation sessions measured by self-report in the Movn Application or through EHR/exercise physiologist report in RedCap	Attending or logging 36 exercise sessions.	12 weeks
Secondary	Type of healthcare utilization by individual participants, defined by routine clinical visits. Urgent care and emergency department visits will be measured using EHR.	Healthcare utilization, defined by routine clinical visits. Urgent care and emergency department visits will be measured using EHR.	6 months
Secondary	Safety measures to track injury from exercise will be assessed using EHR	Injury from exercise will be assessed using EHR including hospitalizations, emergency department visits, urgent care visits and mortality safety endpoints.; They will be captured at the time of occurrence and records will be reviewed by the DSMB.	12 weeks
Secondary	Socioeconomic and clinical data will be collected from EHR.	Sociodemographic and clinical data will be collected from DH registration files including age, gender, self-reported race/ethnicity, primary language preference, comorbid diagnoses (hypertension, diabetes, chronic kidney disease, depression, substance abuse), measures of disease severity (left ventricular ejection fraction, FEV1) and medications.	3.5 yrs